Mustang Bio Q3 net loss narrows to $10.1M; cash drops to $10.3M, raises $4.4M post-quarter

MUSTANG BIO, INC.

2023-Q3 EPS reported -$5.29 vs consensus -$65.03 ▲ beat (+91.9%)

Cash and equivalents $10.3M at Sep 30, down from $16.1M at Jun 30 and $76.7M at Dec 31, 2022.
Net loss of $10.1M ($1.23/share) vs $19.0M ($2.42) in Q3 2022; R&D expenses fell to $9.5M.
CFIUS review of uBriGene asset sale restarted; new 45-day review period began Nov 14, lease transfer delayed.
MB-106 CAR-T showed 95% ORR in follicular lymphoma (n=20) and two complete responses in WM patients.
FDA accepted IND for MB-109 (MB-101 + MB-108) for recurrent glioblastoma; Phase 1 trial planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MUSTANG BIO, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $10.1 million, or $1.23 per share, for the third quarter of 2023, EPS $1.23 per share.

Period: the third quarter ended September 30, 2023
Net income: Net loss attributable to common stockholders was $10.1 million, or $1.23 per share, for the third quarter of 2023
EPS: $1.23 per share
Result: reported results

Exact text from the filing

Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-019052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.